非抗菌细菌疗法市场——技术、市场、战略和预测
市场调查报告书
商品编码
1250861

非抗菌细菌疗法市场——技术、市场、战略和预测

Non-Antibiotic Bacterial Therapeutics - Technologies, Markets, Strategies & Forecasts

出版日期: | 出版商: Greystone Research Associates | 英文 125 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告研究了全球非抗菌细菌疗法市场,并提供了市场概况以及市场未满足的需求、技术趋势、法规和标准以及进入该市场的公司概况。

内容

  • 执行摘要
  • 超越抗生素的细菌治疗
  • 执行摘要
  • 市场动态
  • 未满足的需求
  • 范围定义
  • 抗生素创新的最新发展和需求
  • 不断发展的格局
  • 适合年龄的抗生素
  • 技术
  • 抗体
  • 抗生素灭活□
  • 噬菌体
  • 抗菌□
  • 抗菌纳米粒子
  • 反义治疗/基因沉默
  • 通过膜泵主动流出细菌化合物
  • 多重耐药外排泵的过度表达
  • 铁载体
  • 非抗生素微生物疗法 - 疗法
  • 抗体
  • Aersin (Aridis)
  • Zinprava/bezlotoxumab(默克)
  • 医疗 3902
  • 514G3(X 生物技术)
  • 赖氨酸
  • 噬菌体
  • 抗菌□
  • 防御素
  • Alenisine(Adenium Biotech)
  • Murepavadin (POL7080)(Polyphor Ltd)
  • Host Directed Therapies
  • Univ of Hong Kong
  • Case Western
  • Boston's Children's Hospital
  • 全球市场法规和标准
  • 北美
  • 美国食品药品监督管理局
  • 美国疾病控制中心
  • 欧洲
  • 欧洲疾病预防控制中心
  • 亚洲
  • 中国疾病预防控制中心
  • 国家疾病控制中心
  • 公司简介
简介目录

‘Non-antibiotic Bacterial Therapeutics ’ is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for non-antibiotic therapeutic substances that can treat bacterial infections that are resistant to many or most available antibiotics. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Novel Approaches Creating New Opportunities in Bacterial Therapeutics

As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides currently undergoing clinical trials. The specificity of antibodies, and the inability of bacteria to develop resistance against them, make antibodies attractive, albeit expensive, alternative therapeutic agents. Bacteriophages have been used for therapy in some parts of the world. Antimicrobial peptides have long been considered as potential replacements for antibiotics but with limited success. Synthetic peptides and synthetic Antibiotic membrane-active agents might herald a shift in treatment options.

What You Will Learn:

  • What are the classes of non-antibiotics drugs that can treat bacterial infections alone or in conjunction with existing antibiotics?
  • What non-antibiotic bacterial therapies are in late stage development, who are the developers, and what indications are they targeting?
  • What are the major factors driving demand for non-antibiotic bacterial treatments?
  • What is the size of the market today, who are the market share leaders, and what will the market share be in 2028?
  • What are the essential factors, technologies and market development issues for non-antibiotic bacterial therapeutics products?
  • What are the significant economic, technology, and regulatory factors affecting the market for non-antibiotic bacterial therapies.

Table of Contents

  • Executive Summary
  • Bacterial Therapeutics Beyond Antibiotics
  • Executive Summary
  • Market Dynamics
  • The Unmet Need
  • Defining the Scope
  • Recent Developments and the Need for Antibiotic Innovation
  • The Evolving Landscape
  • Age-appropriate Antibiotics
  • Technology
  • Antibodies
  • Antibiotic-deactivating Enzymes
  • Bacteriophages
  • Antimicrobial peptides
  • Antimicrobial Nanoparticles
  • Antisense therapy/gene silencing
  • Active extrusion of bacterial compounds by membrane pumps
  • Overexpression of Multidrug resistance efflux pumps
  • Siderophores
  • Non-antibiotic Microbial Therapeutics - Therapies
  • Antibodies
  • Aerucin (Aridis)
  • Zinplava/Bezlotoxumab (Merck)
  • MEDI 3902 (MedImmune)
  • 514G3 (XBiotech)
  • Lysins
  • Phages
  • Antimicrobial Peptides
  • Defensins
  • Arenicin (Adenium Biotech)
  • Murepavadin (POL7080) (Polyphor Ltd)
  • Host Directed Therapies
  • Univ of Hong Kong
  • Case Western
  • Boston's Children's Hospital
  • Global Market Regulations and Standards
  • North America
  • US FDA
  • US Centers for Disease Control
  • Europe
  • European Centre for Disease Prevention and Control
  • Asia
  • Chinese Center for Disease Control and Prevention
  • National Centre for Disease Control (India)
  • Company Profiles